An observational study in Staphylococcus Aureus Colonization, sponsored by Washington University School of Medicine. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Washington University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Infections caused by Staphylococcus aureus pose a major public health threat, and existing prevention methods are burdensome to patients and provide only limited benefit. In this collaborative study, participants will trial a probiotic intervention and share their perspectives regarding study design and feasibility. The goal of this study is to characterize colonization kinetics of S. aureus and B. subtilis in the nares, skin, and stool before, during, and after administration of a nutritional supplement probiotic blend. We will establish the S. aureus intestinal colonization kinetics over a 3-month Natural History Phase, followed by a 1-month administration of the probiotic (Intervention Phase), and a 3-month Post-Intervention Observational Phase. Samples from the nares, skin, and stool will be collected at each of the 10 study visits to detect S. aureus and B. subtilis. We will also conduct interviews to assess acceptability, appropriateness, and feasibility of the probiotic and study regimen.
The ongoing epidemic of Staphylococcus aureus skin and soft tissue infections in healthy individuals is a significant public health burden. S. aureus colonization (having the germ living in or on the body without symptoms) poses risk for developing symptomatic S. aureus infections. Thus, topical antimicrobials and antiseptics are often used to eliminate or reduce the burden of S. aureus from the nose and skin (known as decolonization). While current decolonization practices with topical antimicrobials effectively eliminate S. aureus carriage and prevent recurrent infections in the immediate period, their effectiveness wanes over time. While the nose has traditionally been considered the primary reservoir of S. aureus carriage, the intestine is also an important, yet under-appreciated, reservoir of S. aureus. Intestinal colonization can lead to persistent S. aureus colonization at other body sites despite topical antimicrobial decolonization.
Probiotics can promote a healthy gut microbiome by increasing the presence of beneficial bacteria and reducing the presence of pathogens, thereby improving digestive health and enhancing immune function. Bacillus subtilis is a benign microorganism that has been shown to inhibit S. aureus from colonizing the intestine. In a trial conducted in rural Thailand, daily oral administration of B. subtilis MB40 significantly reduced S. aureus in stool and nasal samples, without adverse effects. Bacillus coagulans has been demonstrated to decrease gastrointestinal symptoms, without adverse effects. B. subtilis and B. coagulans are both included as supplements in foods and available in pill form. In this investigation, we will study a probiotic blend of B. subtilis and B. coagulans, which is commercially available as a nutritional supplement, Ameo LifeTM Digest Probiotic. The goals of this study are to 1) establish the longitudinal colonization kinetics of S. aureus and B. subtilis before, during, and after probiotic administration; 2) assess the tolerability and delivery fidelity of the probiotic administration; and 3) engage participant perspectives to optimize study procedures and develop an intervention that is acceptable, appropriate, feasible, and likely to be adopted in real-world settings.
In this study, 20 healthy adults who are at risk for S. aureus infection who are colonized with S. aureus will be enrolled. S. aureus-colonized participants will be followed during a 3-month Natural History Phase, followed by a 1-month administration of the probiotic, and finally, a 3-month Post-Intervention Observational Phase. Stool, nasal, and skin samples will be collected 10 times over 7 months to quantify S. aureus and B. subtilis longitudinally. Participant acceptability and appropriateness will be assessed through brief, semi-structured interviews at the end of the probiotic administration and the conclusion of the Post-Intervention Observational Phase.
304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.
This study's planned enrollment of 20 is below the median of 190 across 91 observational studies indexed under Staphylococcal Infections.
Browse Staphylococcal Infections studies →Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants meeting eligibility criteria who provide written informed consent. Participants will be recruited from a pre-existing participant pool developed through prior studies conducted by our research team. Participants will be from St. Louis, Missouri and surrounding areas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take Ameo Life Digest Probiotic once each day for 30 days. All participants will receive the intervention; there will be no randomization or placebo.
Characterize S. aureus in the stool from the pre-intervention sampling to the Week 4 sampling (completion of the Intervention Phase)
Compare change in S. aureus log10 S. aureus CFU/g count in stool from the pre-intervention sampling to the week-4 (end-of-dosing) sampling.
Time frame: Start of the pre-intervention phase and end of the intervention phase
Evaluate the implementation outcomes of acceptability, appropriateness, and feasibility of the study procedures from the participant's perspective.
Create a participant-informed account of what makes the regimen acceptable and appropriate, benchmarked feasibility data against pre-specified go/no-go thresholds, and a prioritized set of protocol refinements. Comparing facilitators and barriers at the end-of-intervention visit versus the end-of-follow-up visit will indicate whether acceptability changes over time, and benchmarks falling below the thresholds will pinpoint where recruitment, retention, or scheduling procedures require modification.
Time frame: End of the intervention phase and end of the post-intervention phase
S. aureus nares pre-intervention to week-4 (end-of-dosing) sampling.
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-4 (end-of-dosing) sampling.
Time frame: Pre-intervention to week-4 sampling
S. aureus nares pre-intervention to week-6 sampling.
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to week-6 sampling.
Time frame: Pre-intervention to week-6 sampling
S. aureus nares pre-intervention to month 2 sampling.
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 2 sampling.
Time frame: Pre-intervention sampling to month 2 sampling.
S. aureus nares pre-intervention to month 3 sampling.
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 3 sampling.
Time frame: Pre-intervention sampling to month 3 sampling.
S. aureus nares pre-intervention to month 4 sampling.
Change in log10 S. aureus CFU/mL in the nares from the pre-intervention sampling to month 4 sampling.
Time frame: Pre-intervention to month 4 sampling.
S. aureus inguinal fold pre-intervention to week-4 (end-of-dosing) sampling.
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-4 (end-of-dosing) sampling.
Time frame: Pre-intervention to week-4 sampling
S. aureus inguinal fold pre-intervention to week-6 sampling.
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to week-6 sampling.
Time frame: Pre-intervention to week-6 sampling
S. aureus inguinal fold pre-intervention to month 2 sampling.
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 2 sampling.
Time frame: Pre-intervention sampling to month 2 sampling.
S. aureus inguinal fold pre-intervention to month 3 sampling.
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 3 sampling.
Time frame: Pre-intervention sampling to month 3 sampling.
S. aureus inguinal fold pre-intervention to month 4 sampling.
Change in log10 S. aureus CFU/mL in the inguinal fold from the pre-intervention sampling to month 4 sampling.
Time frame: Pre-intervention sampling to month 4 sampling.
Bacillus stool pre-intervention
log10 B. subtilis CFU count at pre-intervention sampling
Time frame: Pre-intervention sampling
Bacillus stool week-2 sampling
log10 B. subtilis CFU count at week-2 sampling
Time frame: Week-2 sampling
Bacillus stool week-4 sampling
log10 B. subtilis CFU count at week-4 sampling
Time frame: Week-4 sampling
Bacillus stool week-6 sampling
log10 B. subtilis CFU count at week-6 sampling
Time frame: Week-6 sampling
Bacillus stool month 2 sampling
log10 B. subtilis CFU count at month 2 sampling
Time frame: Month 2 sampling
Bacillus stool month 3 sampling
log10 B. subtilis CFU count at month 3 sampling
Time frame: Month 3 sampling
Bacillus stool month 4 sampling
log10 B. subtilis CFU count at month 4 sampling
Time frame: Month 4 sampling
No study locations are listed for this record.
Plan to share: No
Start is estimated for Nov 2026; primary completion for Nov 2030, 48 months later.
Of 22 observational studies under Staphylococcal Infections, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's planned 48 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →